Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847420 | 0.90 | CYP1A2 (0.38) | ALDH1A1CYP1A2HPGDHSD17B10KMT2A | |
| SCHEMBL973485 | 0.86 | HNF4A (0.40) | ALDH1A1CYP1A2HPGDHSD17B10HNF4A | |
| SCHEMBL29424688 | 0.86 | HNF4A (0.40) | ALDH1A1CYP1A2HPGDHSD17B10HNF4A | |
| SCHEMBL12588926 | 0.82 | KMT2A (0.35) | ALDH1A1HPGDKMT2AKDM4ERAB9A | |
| SCHEMBL10109864 | 0.78 | HNF4A (0.45) | ALDH1A1CYP1A2HPGDHSD17B10HNF4A | |
| SCHEMBL12964671 | 0.75 | KDM4E (0.31) | CYP1A2KDM4EL3MBTL1ATMCYP2A6 | |
| SCHEMBL12808381 | 0.74 | HNF4A (0.38) | ALDH1A1CYP1A2HPGDHSD17B10HNF4A | |
| SCHEMBL4665721 | 0.74 | ABCG2 (0.34) | ALDH1A1CYP1A2HPGDHSD17B10HNF4A | |
| SCHEMBL13425164 | 0.74 | CYP1A2 (0.41) | ALDH1A1CYP1A2HPGDHSD17B10KMT2A | |
| SCHEMBL12936999 | 0.73 | KDM4E (0.31) | KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314238-B2 | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314238-B2 | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8247560-B2 | Trisubstituted 3,4-dihydro-1H-isoquinolin compound, process for its preparation, and its use | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247560-B2 | Trisubstituted 3,4-dihydro-1H-isoquinolin compound, process for its preparation, and its use | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20100305325-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305325-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100010226-A1 | TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20100010226-A1 | TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010226-A1 | TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE | CYP3A7, UGT1A7, CYP51A1 | ALDH1A1 382/4885CYP1A2 7/4885HPGD 609/4885 |
| US-20100305325-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | DHPS, CISD1, CISD2 | ALDH1A1 393/4885CYP1A2 33/4885HPGD 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.